Positions Open at 陳緯老師實驗室 / Dr. Wei Chen's Lab

• Place：
  台北市南港區研究院路二段128號基因體研究中心陳緯老師實驗室 / Wei Chen Lab at the Genomics Research Center, Academia Sinica
• Title：
  博士後研究學者 / Postdoctoral Researcher
• Responsibilities：
  1. 設計與合成新穎奈米材料，生物材料，或可提供疾病治療的生物醫學材料與方法。
  
  2. 細胞培養與分子生物學實驗。
  
  3. 小鼠動物實驗 (如疾病模式的建立，評估疾病治療的效果等)。
  
  可獨立完成其中1-2項者佳，能獨立完成這3項實驗者優先考慮。
  
  
  
  1. Design and synthesis of innovative nanomaterials, biomaterials, or biomedical materials and methods for disease treatment.
  
  2. Cell culture and molecular biology experiments.
  
  3. Mouse animal experiments, such as establishing disease models and assessing the effectiveness of disease treatment.
  
  It is preferable if the applicants can independently complete at least 1-2 of these tasks, and those who can independently complete all 3 tasks will be given priority consideration.
• Qualification：
  學歷或科系 / Qualification
  
  化學，生命科學，生物醫學工程，生物化學，免疫，醫學，藥學，材料科學工程，化學工程等相關科系，具博士學位。
  
  
  
  With a background of chemistry, biology, biomedical engineering, biochemistry, immunology, medicine, pharmacology, materials science engineering, or chemical engineering-related degree/program
  
  
  
  徵求條件 / Qualification
  
  1. 熟悉實驗室常規工作。
  
  2.對研究工作有熱忱、責任感、細心、耐心，能獨立操作實驗，具團隊合作精神。
  
  3.能獨立操作奈米材料合成或動物實驗者佳。
  
  1. Familiarity with routine lab work.
  
  2. Self-motivation, responsibility, and a team-oriented mindset.
  
  3. A preference for the ability to independently conduct nanomaterials synthesis or animal experiments.
• Contact：
  Dr.陳緯 / Dr.Chen Wei
• Telephone：
  02-27871299
• Email：
  wchen123@gate.sinica.edu.tw
• Address：
  11529台北市南港區研究院路二段128號基因體研究中心陳緯老師實驗室 / Wei Chen Lab at the Genomics Research Center, Academia Sinica
• Documents：
  履歷(附照片)、自傳、最高學歷畢業證書、經歷證明，請提供二~三位推薦人聯絡方式。
  
  CV or resume and the contact information of 2-3 references.
• Remark：
  本實驗室著重於發展奈米醫學，藥物輸送，RNA奈米技術，生物醫學工程，生物材料，與化學的技術與方法進行癌症，炎症相關疾病的治療，以解決目前疾病治療上之醫學瓶頸。
  
  The Chen Lab’s priority is to continue developing innovative nanomaterials, RNA nanotechnology, synthetic biomaterials, living materials, and biomedical engineering approaches in cancer and inflammatory disease treatment and translational medicine for better human healthcare. The Chen Lab welcomes inquisitive, passionate scientists, engineers and medical doctors who take a creative approach to their research, dare to think big and follow new ideas wherever they lead. The Chen Lab supports creative, timely research to spark fresh thinking and produce effective, innovative solutions to address the critical challenges in human disease treatment. Additionally, the Chen Lab is committed to supporting the career development of group members at all level of researchers.
  
  We Create Breakthroughs, We Pursue Excellence, and We’re Stronger Together.
  
  
  
  Principle Investigator (PI) Bio
  
  The PI, Wei Chen, Ph.D., received his BS and MS degrees in Chemistry at National Taiwan University (NTU), PhD degree in Chemistry and Biochemistry at University of California Los Angeles (UCLA), and Postdoctoral Research in Nanomedicine and drug delivery at Brigham and Women's Hospital, Harvard Medical School. Dr. Chen has established exceptional expertise in the research field of nanobiotechnology, with emphasis on nanomedicine, drug delivery, biomedical engineering, immunology, and nano-bio interactions. His research involves a highly interdisciplinary combination of nanomaterial synthesis, stimuli-responsive materials design and development, two-dimensional (2D) materials, porous materials, nano-cell interaction, chemotherapy, sonodynamic therapy, macrophage immunology, bioimaging, as well as small molecules/siRNA/DNA/mRNA delivery. During his Ph.D. training with Professor Jeffrey I. Zink in University of California Los Angeles (UCLA), he had been worked with world experts at Chemistry, Radiological Sciences, and Microbiology, and Immunology Department in Medical School of UCLA to develop stimuli (magnetic field, ultrasound, and light)-responsive biomaterials for controlled drug delivery for cancer and tuberculosis treatments. Additionally, during his postdoctoral training with Professor Wei Tao and Director/Professor Omid C. Farokhzad in Center for Nanomedicine, Brigham and Women’s Hospital, Harvard Medical School, he has been worked with world experts and medical doctors at Harvard Medical School and Massachusetts Institute of Technology (MIT) to develop the design of (i) mRNA nanoparticles for inflammatory disease treatment, (ii) 2D materials for photothermal and sonodynamic therapy as well as drug delivery for the treatment of cancer and inflammatory diseases and (iii) innovative living materials (e.g. microalgae) for the treatment of gastrointestinal disease (colon cancer and inflammatory bowel disease) by modulating the local immune responses.
  
  Dr. Chen has so far authored 50+ peer-reviewed papers including 20+ first-author or corresponding-author papers in high-impact journals, such as
  
  1. Nature Reviews Cardiology 2022, 19, 228-249 (Front Cover Featured);
  
  2. Nature Communications, 2023, 10.1038/s41467-023-42509-7;
  
  3. Science Advances 2021, 7, abi9265 (Front Cover Paper);
  
  4. J. Am. Chem. Soc. 2023, 145, 8375-8388 (Cover Featured);
  
  5. J. Am. Chem. Soc. 2019, 141, 12475-12480;
  
  6. J. Am. Chem. Soc. 2019, 141, 17670-17684;
  
  7. Angew. Chem. Int. Ed. 2023, 62, e202308413 (Front Cover Paper, Top 5% VIP),
  
  8. Angew. Chem. Int. Ed. 2021, 60, 7155-7164 (Front Cover Paper, Top 5% VIP);
  
  9. Chem. Rev. 2023 in press;
  
  10. Acc. Chem. Res. 2019, 52, 1531-1542;
  
  11. ACS Nano 2019, 13, 1292-1308;
  
  12. ACS Nano 2013, 7, 8423-8440;
  
  13. Matter (Cell Press) 2022, 5, 2471-247;
  
  14. Matter (Cell Press) 2022, 5, 18-19;
  
  15. Advanced Science 2023, 10, 2207439;
  
  16. Advanced Science 2023, 10, 2207768,
  
  17. Biomaterials 2023, 295, 122031,
  
  18. ACS Appl. Mater. Interfaces 2018, 10, 31870-31881, etc.
  
  Many of these papers have been rated as Top 1% ESI Highly Cited Paper.
  
  Additionally, Dr. Chen has been dedicated to serving as an exceptional collaborator, and through these collaborations, we have achieved numerous high-impact papers, including publications in journals, such as
  
  1. Nature Reviews Methods Primers 2023, 3, 63;
  
  2. Proc. Natl. Acad. Sci. U.S.A. 2023, 120, e2304966120;
  
  3. Nature Communications 2021, 12, 1124;
  
  4. Nature Communications 2022, 13, 1413;
  
  5. J. Am. Chem. Soc. 2023, 145, 12193–12205;
  
  6. Chemical Society Reviews 2022, 51, 3828-3845;
  
  7. Advanced Materials 2023, 35, 2207391;
  
  8. Advanced Materials 2023, 35, 2207787;
  
  9. Advanced Materials 2021, 33, 2102504;
  
  10. Materials Today 2023, 62, 296-326;
  
  11. Nano Letters 2021, 21, 9706-9714;
  
  12. Advanced Drug Delivery Reviews 2022, 185, 114268, etc.
• Deadline：
  2024-06-30